Advertisement

COX-2 Inhibitors in Cancer Cachexia

  • Giovanni Mantovani

Abstract

Cyclo-oxygenase-2 (COX-2) is an enzyme catalysing the synthesis of prostaglandins (PGs) from arachidonic acid. Cells contain genes coding for two isoforms of COX (COX-1 and COX-2). COX-1 is expressed constitutively in most tissues and appears to be responsible for the production of PGs that mediate normal physiological functions, such as maintenance of the integrity of the gastric mucosa and regulation of renal blood flow. In contrast, COX-2 is undetectable in most normal tissues: it is induced by cytokines, growth factors, oncogenes and tumour promoters, and it contributes to the synthesis of PGs in inflamed and neoplastic tissues [1]. COX-2 is induced in many human tumours and is associated with aberrant angiogenesis in a number of pathological settings, especially those involving inflammation. It has been well demonstrated that dysregulation of COX-2 expression correlates with development of gastrointestinal cancers.

Keywords

Cancer Cachexia Indomethacin Treatment Advanced Lung Adenocarcinoma Prostaglandin Leukot Essent Fatty Acid Aberrant Angiogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125–140PubMedGoogle Scholar
  2. 2.
    Sano H, Kawahito Y, Wilder RL et al (1995) Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 55:3785–3789PubMedGoogle Scholar
  3. 3.
    Lupulescu A (1996) Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54:83–94PubMedCrossRefGoogle Scholar
  4. 4.
    Bennett A (1986) The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 25:539–542PubMedCrossRefGoogle Scholar
  5. 5.
    Eling TE, Thompson DC, Foureman GL et al (1990) Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30:1–45PubMedGoogle Scholar
  6. 6.
    Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501PubMedCrossRefGoogle Scholar
  7. 7.
    Weitzman SA, Gordon LI (1990) Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76:655–663PubMedGoogle Scholar
  8. 8.
    Kambayashi T, Alexander HR, Fong M, Strassmann G (1995) Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383–3390PubMedGoogle Scholar
  9. 9.
    Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  10. 10.
    Gallo O, Franchi A, Magnelli L et al (2001) Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3:53–61PubMedCrossRefGoogle Scholar
  11. 11.
    Eling TE, Curtis JF (1992) Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 53:261–273PubMedCrossRefGoogle Scholar
  12. 12.
    Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  13. 13.
    Moore RJ, Zweifel B, Heuvelman DM et al (2000) Enhanced antitumor activity by co-administration of celecoxib and chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Assoc Cancer Res 41:409Google Scholar
  14. 14.
    Kishi K, Petersen S, Petersen C et al (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326–1331PubMedGoogle Scholar
  15. 15.
    Dicker AP (2003) COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting. Am J Clin Oncol 26:S46–S47PubMedGoogle Scholar
  16. 16.
    Davis TW, Zweifel BS, O’Neal JM et al (2004) Inhibition of COX-2 by celecoxib reverses tumor induced wasting. J Pharmacol Exp Ther 308:929–934PubMedCrossRefGoogle Scholar
  17. 17.
    Seyberth HW, Segre GV, Sweetmen BJ et al (1975) Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 293:1278–1285PubMedCrossRefGoogle Scholar
  18. 18.
    Thompson MG, Palmer RM (1998) Signalling pathways regulating protein turnover in skeletal muscle. Cell Signal 10:1–11PubMedCrossRefGoogle Scholar
  19. 19.
    Rothwell NJ (1992) Eicosanoids, thermogenesis and thermoregulation. Prostaglandins Leukot Essent Fatty Acids 46:1–7PubMedCrossRefGoogle Scholar
  20. 20.
    Smith KL, Tisdale MJ (1993) Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 68:314–318PubMedGoogle Scholar
  21. 21.
    Homem-de-BittencourtJr PI, Pontieri V, Curi R, Lopes OU (1989) Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. Braz J Med Biol Res 22:1039–1042Google Scholar
  22. 22.
    McCarthy DO (1999) Inhibitors of prostaglandin synthesis do not improve food intake or body weight of tumor-bearing rats. Res Nurs Health 22:380–387PubMedCrossRefGoogle Scholar
  23. 23.
    McEntee MF, Chiu CH, Whelan J (1999) Relationship of b-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20:635–640PubMedCrossRefGoogle Scholar
  24. 24.
    Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18:7908–7916PubMedCrossRefGoogle Scholar
  25. 25.
    Jacoby RF, Scibert K, Cole CE et al (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040–5044PubMedGoogle Scholar
  26. 26.
    Masferrer J (2001) Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 7(Suppl 3):S144–S150PubMedGoogle Scholar
  27. 27.
    Leahy KM, Ornberg RL, Wang Y et al (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625–631PubMedGoogle Scholar
  28. 28.
    Zweifel BS, Davis TW, Ornberg RL, Masferrer JL (2002) Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 62:6706–6711PubMedGoogle Scholar
  29. 29.
    Johnson PM, Vogt SK, Burney MW, Muglia LJ (2002) COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am J Physiol Endocrinol Metab 282:E650–E656PubMedGoogle Scholar
  30. 30.
    Hussey HJ, Tisdale MJ (2000) Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 87:95–100PubMedCrossRefGoogle Scholar
  31. 31.
    Okamoto T (2002) NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAIDs (Review). Int J Mol Med 9:369–372PubMedGoogle Scholar
  32. 32.
    McMillan DC, Leen E, Smith J et al (1995) Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 21:531–534PubMedCrossRefGoogle Scholar
  33. 33.
    Preston T, Fearon KC, McMillan DC et al (1995) Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 82:229–234PubMedCrossRefGoogle Scholar
  34. 34.
    Wigmore SJ, Falconer JS, Plester CE et al (1995) Ibuprofen reduces energy expenditure and acutephase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 72:185–188PubMedGoogle Scholar
  35. 35.
    Lundholm K, Gelin J, Hyltander A et al (1994) Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602–5606PubMedGoogle Scholar
  36. 36.
    McMillan DC, Wigmore SJ, Fearon KC et al (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79:495–500PubMedCrossRefGoogle Scholar
  37. 37.
    Lundholm K, Daneryd P, Korner U et al (2004) Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24:505–512PubMedGoogle Scholar
  38. 38.
    Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95PubMedCrossRefGoogle Scholar
  39. 39.
    Hague TA, Christoffersen BO (1984) Effect of dietary fats in arachidonic acid and eicosapentaenoic acid biosynthesis and conversion of C22 fatty acids in isolated liver cells. Biochim Biophys Acta 796:205–217Google Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Giovanni Mantovani
    • 1
  1. 1.Department of Medical OncologyUniversity of CagliariCagliariItaly

Personalised recommendations